{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neutropenic-sepsis/background-information/complications/","result":{"pageContext":{"chapter":{"id":"1b791a2a-8fd9-5d7c-8986-d1e27bf8e0dc","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 523f781e-03de-48ad-8ec0-aa7100a58dfa --><h2>What are the complications?</h2><!-- end field 523f781e-03de-48ad-8ec0-aa7100a58dfa -->","summary":"","htmlStringContent":"<!-- begin item 30f8caac-4fce-4c77-a734-aa7100a58dd7 --><!-- begin field 9f45271f-38c9-47ee-9f8e-aa7100a58dfa --><p><strong>Up to 50% of cases of febrile neutropenia have no significant complications or evidence of infection </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Morgan, 2018</a>]<strong>. If neutropenic sepsis develops, possible complications include:</strong></p><ul><li>Death<ul><li>Sepsis and septic shock are leading causes of death in people with haematological or solid tumours with chemotherapy-induced neutropenia. Neutropenia is an independent risk factor for increased mortality in this population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Kochanek, 2019</a>].</li></ul></li><li>Organ failure<ul><li>This may be multi-system and includes acute kidney injury (AKI), cholestasis, heart failure, acute respiratory distress syndrome (ARDS) or acute lung injury, and bone marrow suppression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Clarke, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Gotts, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Cecconi, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Morgan, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Kochanek, 2019</a>]. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/acute-kidney-injury/\">Acute kidney injury</a>, <a class=\"topic-reference external-reference\" href=\"/topics/jaundice-in-adults/\">Jaundice in adults</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a> for more information.<ul><li>Neutropenia is independently associated with a higher risk for AKI compared with non-neutropenic sepsis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Reilly, 2016</a>].</li><li>Multiple previous chemotherapy treatments may independently increase the risk of developing heart failure, depending on the regimens used [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Kochanek, 2019</a>].</li></ul></li></ul></li><li>Invasive and atypical infection<ul><li>People with neutropenic sepsis may develop opportunistic or hospital-acquired infections with atypical organisms such as Legionella sp and Mycoplasma sp, and may have reactivation of latent viruses, due to an impaired ability to mount an appropriate immune response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Gotts, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Klastersky, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Cecconi, 2018</a>].</li><li>People receiving chemotherapy for acute myeloid leukaemia and undergoing haematopoietic stem cell transplantation are at risk of prolonged neutropenia and invasive fungal or atypical infections, such as systemic candidiasis and aspergillosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Clarke, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Klastersky, 2016</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/candida-oral/\">Candida - oral</a> for more information.</li></ul></li><li>Neutropenic enterocolitis<ul><li>An acute life-threatening condition characterized by transmural inflammation of the caecum, often with involvement of the ascending colon and ileum, which is then vulnerable to bacterial intramural invasion. It typically presents with abdominal pain, diarrhoea, and fever [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Clarke, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Rodrigues, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Georges, 2018</a>].</li></ul></li><li>Malnutrition<ul><li>This may be partly due to impaired intestinal barrier function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Gotts, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Daniels, 2017</a>].</li></ul></li><li>Coagulopathy<ul><li>This may cause thromboembolism or disseminated intravascular coagulation (DIC) characterized by microthrombosis and haemorrhage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Clarke, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Cecconi, 2018</a>]. Microvascular changes and DIC can result in loss of digits or limbs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Daniels, 2017</a>]. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/deep-vein-thrombosis/\">Deep vein thrombosis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/pulmonary-embolism/\">Pulmonary embolism</a> for more information.</li></ul></li><li>Physical impairments<ul><li>A reduced quality of life may result from chronic pain and fatigue [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Winters, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Gauer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Daniels, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Cecconi, 2018</a>].</li></ul></li><li>Encephalopathy and delirium<ul><li>This may lead to reduced mobility and neuromuscular weakness, as well as longer lasting neurocognitive deficits such as memory problems and reduced concentration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Daniels, 2017</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/delirium/\">Delirium</a> for more information.</li></ul></li><li>Psychological sequelae<ul><li>These may include anxiety about recurrent infection and sepsis, post-traumatic stress disorder, loss of confidence and self-esteem, and social isolation due to fear of infection from others [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Gauer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Warnock, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Daniels, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Cecconi, 2018</a>]. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/post-traumatic-stress-disorder/\">Post-traumatic stress disorder</a> for more information.</li></ul></li><li>Treatment delays and reductions in dose intensity<ul><li>Neutropenic sepsis may affect drug regimens of chemotherapy or other immunosuppressive drug therapy, leading to reduced drug efficacy and impact on cancer treatment outcomes, including disease-free intervals and survival rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Klastersky, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Warnock, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Morgan, 2018</a>].</li></ul></li></ul><!-- end field 9f45271f-38c9-47ee-9f8e-aa7100a58dfa --><!-- end item 30f8caac-4fce-4c77-a734-aa7100a58dd7 -->","topic":{"id":"c8aa50da-234b-5d4d-b2b3-1ae1d89115e0","topicId":"08d261eb-f269-42a7-801b-2cfddf69a31c","topicName":"Neutropenic sepsis","slug":"neutropenic-sepsis","lastRevised":"Last revised in March 2020","chapters":[{"id":"ade08997-70b7-5f71-ace1-e47c80bdc07a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"999bcfa1-3c00-58e5-8186-5b889008a21f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9ff15809-1783-50bc-8cc4-5fb56eb08252","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1c09fe06-1c69-51ad-8cc6-a0823851753f","slug":"changes","fullItemName":"Changes"},{"id":"1914dca9-ff88-5330-9b92-27f7df59493c","slug":"update","fullItemName":"Update"}]},{"id":"ed21973f-408a-58e8-912b-7bd2b9d0b718","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58b41c14-2b33-5d1a-b538-099b3fca97fa","slug":"goals","fullItemName":"Goals"},{"id":"c647afae-0cce-504a-b6c3-2af1cf1df43b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9ef3011a-bd82-5da3-ad4c-e33e63dfb333","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1ff2a9b1-3f7b-5c06-8db0-0061ed24ddb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"eea45e78-ce2a-5043-85e2-4acda94fa67e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"167786d0-fb09-53a6-b02d-05105c74f541","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bafe86b3-b06d-52ce-9da2-4373bfa1b619","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4adba361-ab85-5502-b0b7-ccd33f58b0f9","slug":"definition","fullItemName":"Definition"},{"id":"048bb40e-2b5d-5e2d-8205-4cb6c5986b71","slug":"causes","fullItemName":"Causes"},{"id":"53c0b23f-7fa2-5824-b31e-6277f40216a8","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"751f6798-f767-50f9-b2b5-b23b45bc02cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1b791a2a-8fd9-5d7c-8986-d1e27bf8e0dc","slug":"complications","fullItemName":"Complications"},{"id":"432b2287-33da-5d24-bf96-4c7e3cf898a9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2422aa1e-8340-5487-8466-e27286e03762","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"338f02ac-53b8-56c4-a0d0-df9873cabe95","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"292306b5-1418-5247-90d7-fe7ddd283226","slug":"assessment","fullItemName":"Assessment"}]},{"id":"a7a279c8-f7ee-50ec-90b2-5441d36ecceb","fullItemName":"Management","slug":"management","subChapters":[{"id":"28f8b375-c46b-5444-98d8-f753fae4bcfa","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"5a36b1f2-e382-5001-8945-0cef6e53ec83","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c0e91f63-5078-5363-b15a-7db7cc483396","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"740f1b28-1eb9-5160-9dd6-5a1e00f5e8c1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"17c51bf6-cc58-58c7-8a0a-d6caed83c5b6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c53a0347-9a44-5b20-b1b4-1adfa5b3f959","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"460cc4fe-21c5-57de-9ae3-4c27bc1ab338","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a88ff1aa-1ddd-5785-a592-ebfafff8da3e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8205950b-1254-5a4b-a51a-4a887c9da60d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bafe86b3-b06d-52ce-9da2-4373bfa1b619","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}